Image may be NSFW.
Clik here to view.
The FDA approved Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon to treat long superficial femoral artery lesions up to 360mm in patients with peripheral artery disease, the medtech giant touted today.
In a 227-patient global trial, participants treated with Medtronic’s drug-device combination therapy had a one-year patency rate of 89.1% and a clinically-driven target revascularization rate of 7.1%.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Medtronic’s drug-coated balloon to treat long superficial femoral artery lesions appeared first on MassDevice.
